Welcome to Storyflo Daily Biotech. I'm Bea. Today, we're buzzing with game-changing stories from the world of neurology, pharma, and biotech

First up, we're looking beyond the usual suspects in neurology. Labiotech.eu is reporting on the emergence of novel technologies that are revolutionizing the field. While you've probably heard of amyloid and dopamine, experts are now exploring alternative avenues to tackle neurological disorders. According to Labiotech.eu, researchers are investigating novel targets like the synapse, axons, and even the gut-brain axis. This shift in focus has the potential to unlock new treatments and therapies, and we'll be keeping a close eye on these developments. Next, we're moving to Spain, which is rapidly becoming a hotspot for pharma and biotech innovation. Labiotech.eu says the country's scientific excellence, leadership in clinical trials, and growing investment appeal are drawing in global talent and money. With pharmaceutical giants like Pfizer already setting up shop in the region, it's clear that Spain is poised to play a significant role in shaping the future of biotech. And in a special episode, Labiotech.eu is celebrating 200 episodes of their podcast with a chat with Joachim Eeckhout, the co-founder of Labiotech. Eeckhout shares insights on the evolution of Labiotech, the changing media landscape, and his vision for the future of biotech. His comments are a great reminder that the biotech industry is constantly evolving, and staying informed requires a keen eye on innovation and disruption. Today's stories show us that the biotech universe is teeming with new ideas, investment, and innovation. Whether it's the next breakthrough in neurology, the rise of a new biotech hub, or the power of storytelling in shaping the industry's narrative, we're witnessing a thrilling era of growth and experimentation.